Prot# CEL220: A Phase IV, Single Center Pilot Study Using Alemtuzumab (CAMPATH-1H) Induction Combined with Prednisone-Free and Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation

Project: Research project

Project Details

StatusFinished
Effective start/end date1/25/0511/1/11

Funding

  • Roche Laboratories Inc. (CEL220)